Herceptin Global Market Report 2025

The herceptin market size has grown strongly in recent years. It will grow from$7.1 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to regulatory approvals, the rising incidence of breast cancer, advancements in monoclonal antibody technology, positive clinical trial outcomes, and increasing healthcare expenditure.

The herceptin market size is expected to see strong growth in the next few years. It will grow to$9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, improved healthcare access in emerging markets, ongoing research and development in oncology, and the rising prevalence of HER2-positive cancers. Key trends in the forecast period include the development of antibody-drug conjugates, advancements in biosimilar formulations, the integration of AI in drug discovery, personalized medicine approaches, and improvements in drug delivery systems.

The growing incidence of breast cancer is expected to drive the expansion of the Herceptin market. Breast cancer, which develops in the cells of the breast, typically starts in the milk ducts or lobules, and includes types such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer cases is partly attributed to lifestyle factors such as higher alcohol consumption, poor diet, and a lack of physical activity, all of which contribute to a higher risk. As more individuals, particularly those diagnosed with HER2-positive breast cancer, are seeking treatment, the demand for effective targeted therapies such as Herceptin continues to grow. For instance, in January 2025, the American Cancer Society projected approximately 319,750 new cases of breast cancer in the U.S. with 42,680 expected deaths. Therefore, the increasing incidence of breast cancer is fueling the growth of the Herceptin market.

Leading companies in the Herceptin market are developing innovative biosimilar products to improve patient access and enhance therapeutic outcomes for HER2-positive cancers. Biosimilars are highly similar versions of approved biologic drugs, developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI provide patients with a cost-effective treatment option while maintaining comparable efficacy and safety to the original biologic drug.

In December 2022, Celltrion Inc., a South Korea-based biopharmaceutical company, merged with Celltrion Healthcare Co. to enhance its cost competitiveness and diversify its product pipeline. This merger is designed to streamline operations, boost research investments, and simplify the company's structure. Celltrion Healthcare Co., known for developing the Herceptin biosimilar Herzuma (trastuzumab-pkrb), which was approved by the FDA, is now positioned to further strengthen its global biopharma presence following this strategic merger.

Major players in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy’s Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., and Prestige Biopharma Pte Ltd.

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herceptin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, Herceptin inhibits tumor cell proliferation and marks them for destruction by the immune system.

The main products of Herceptin include biologics and biosimilars. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The key payers include commercial, private, and public sectors, with applications in the treatment of breast and gastric cancers. Treatment is distributed through various channels, such as hospital pharmacies and specialty pharmacies.

The herceptin market research report is one of a series of new reports that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.